APLS · Apellis Pharmaceuticals, Inc.
Market Cap
$5.25B
Shares
128.02M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1B
+28.5%
FY2025
Net Income
$22.39M
+111.3%
FY2025
Operating Margin
5.52%
+26.6pp
FY2025
Diluted EPS
$0.20
+112.5%
FY2025
Operating Cash Flow
$45.33M
+151.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.11B | $1B | $781.37M | $396.59M | $75.42M | $66.56M | $250.65M | — | — | — | — | — | |
| $286.39M | $295.85M | $327.57M | $354.39M | $387.24M | $345.87M | $299.92M | $220.97M | $105.29M | $40.3M | $22.98M | $13.73M | |
| — | — | — | $500.82M | $277.16M | $176.77M | $139.4M | $67.05M | $22.64M | $10.46M | $4.3M | $6.36M | |
| $545.24M | $550.27M | $501.05M | $500.82M | $277.16M | — | — | — | — | — | — | — | |
| $940.06M | $948.36M | $946.35M | $913.71M | $670.04M | $602.84M | $464.37M | $288.02M | $127.93M | — | — | — | |
| $165.22M | $55.43M | -$164.98M | -$517.12M | -$594.61M | -$536.28M | -$213.73M | -$288.02M | -$127.93M | -$50.77M | -$27.28M | -$46.57M | |
| — | 5.52% | -21.11% | -130.39% | -788.38% | -805.67% | -85.27% | — | — | — | — | — | |
| $43.6M | $44.33M | $40.39M | $29.58M | $32.63M | — | — | — | — | — | — | — | |
| $120K | -$133K | -$2.17M | -$727K | -$288K | $1.36M | -$501K | -$175K | -$25K | -$142.15K | $22.4K | — | |
| $135.15M | $24.11M | -$196.72M | -$526.5M | -$651.5M | -$746M | -$343.03M | -$304.71M | -$127.5M | -$51.01M | — | — | |
| $1.88M | $1.72M | $1.16M | $2.13M | $669K | $352K | $1.85M | — | — | — | — | — | |
| $133.27M | $22.39M | -$197.88M | -$528.63M | -$652.17M | -$746.35M | -$344.87M | -$304.71M | -$127.5M | -$51.01M | -$27.12M | -$46.52M | |
| — | 2.23% | -25.32% | -133.29% | -864.7% | -1121.27% | -137.59% | — | — | — | — | — | |
| $133.91M | $23.59M | -$197.64M | -$531.3M | -$650.96M | -$748.33M | -$344.84M | -$304.74M | -$127.63M | -$51.01M | -$27.12M | — | |
| USD/shares | — | $0.18 | -$1.60 | -$4.45 | -$6.15 | -$8.84 | -$4.59 | — | — | — | — | — |
| USD/shares | — | $0.20 | -$1.60 | -$4.45 | -$6.15 | -$8.84 | -$4.59 | — | — | — | — | — |
| shares | — | 126.15M | 123.91M | 118.68M | 106.11M | 84.42M | 75.16M | 62.23M | 54.4M | 13.87M | 8.43M | 5.8M |
| shares | — | 129.86M | 123.91M | 118.68M | 106.11M | 84.42M | 75.16M | 62.23M | 54.4M | 13.87M | 8.43M | 5.8M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.46×
EV/EBIT
—
Peer median 27.68×
P/E (TTM)
—
Peer median 17.79×
Peer medians compare against the 196 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $1,003,782,000 | $781,367,000 | $396,591,000 | $75,422,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $689,383,000 | $709,954,000 | $366,281,000 | $65,092,000 | $15,147,000 | — |
| Syfovre | $586,934,000 | $611,863,000 | $275,248,000 | — | — | — |
| Licensing and Other Revenue | $314,399,000 | $71,413,000 | $30,310,000 | $10,330,000 | $51,416,000 | $250,646,000 |
| Empaveli Pegcetacoplan | $102,449,000 | $98,091,000 | $91,033,000 | $65,092,000 | $15,147,000 | — |